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BACKGROUND
A universal testing and treatment strategy is a potential approach to reduce the incidence of 
human immunodeficiency virus (HIV) infection, yet previous trial results are inconsistent.
METHODS
In the HPTN 071 (PopART) community-randomized trial conducted from 2013 through 
2018, we randomly assigned 21 communities in Zambia and South Africa (total population, 
approximately 1 million) to group A (combination prevention intervention with universal 
antiretroviral therapy [ART]), group B (the prevention intervention with ART provided ac-
cording to local guidelines [universal since 2016]), or group C (standard care). The preven-
tion intervention included home-based HIV testing delivered by community workers, who 
also supported linkage to HIV care and ART adherence. The primary outcome, HIV incidence 
between months 12 and 36, was measured in a population cohort of approximately 2000 
randomly sampled adults (18 to 44 years of age) per community. Viral suppression (<400 
copies of HIV RNA per milliliter) was assessed in all HIV-positive participants at 24 months.
RESULTS
The population cohort included 48,301 participants. Baseline HIV prevalence was 21% or 
22% in each group. Between months 12 and 36, a total of 553 new HIV infections were 
observed during 39,702 person-years (1.4 per 100 person-years; women, 1.7; men, 0.8). The 
adjusted rate ratio for group A as compared with group C was 0.93 (95% confidence inter-
val [CI], 0.74 to 1.18; P = 0.51) and for group B as compared with group C was 0.70 (95% 
CI, 0.55 to 0.88; P = 0.006). The percentage of HIV-positive participants with viral suppres-
sion at 24 months was 71.9% in group A, 67.5% in group B, and 60.2% in group C. The 
estimated percentage of HIV-positive adults in the community who were receiving ART at 
36 months was 81% in group A and 80% in group B.
CONCLUSIONS
A combination prevention intervention with ART provided according to local guidelines 
resulted in a 30% lower incidence of HIV infection than standard care. The lack of effect 
with universal ART was unanticipated and not consistent with the data on viral suppres-
sion. In this trial setting, universal testing and treatment reduced the population-level 
incidence of HIV infection. (Funded by the National Institute of Allergy and Infectious 
Diseases and others; HPTN 071 [PopArt] ClinicalTrials.gov number, NCT01900977.)
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In 2017, approximately 37 million people were living with human immunodeficiency virus (HIV) infection worldwide, with 1.8 mil-
lion new infections that year.1 HIV incidence is 
declining worldwide but is unlikely to reach the 
Joint United Nations Program on HIV/AIDS 
(UNAIDS) target of less than 500,000 new infec-
tions per year by 2020.2 Steep reductions in inci-
dence are needed to curb the HIV–acquired im-
munodeficiency syndrome (AIDS) epidemic.
A universal testing and treatment strategy 
has been proposed as an important component 
of HIV combination prevention programs.3,4 The 
HIV Prevention Trials Network (HPTN) 052 trial 
showed that early initiation of antiretroviral 
therapy (ART) dramatically reduced HIV trans-
mission among couples,5,6 and the Partners of 
People on ART — A New Evaluation of the Risks 
(PARTNER) study showed that viral suppression 
(<200 copies per milliliter) prevented sexual 
transmission of HIV.7,8 Mathematical modeling 
predicted that HIV incidence would fall steeply if 
HIV testing were provided throughout a popula-
tion and ART initiated immediately after diag-
nosis.9-11 Early ART also confers individual health 
benefits.12,13 In 2014, UNAIDS proposed that by 
2020, 90% of HIV-positive persons should know 
their status, 90% of those persons (i.e., 81% of 
HIV-positive persons) should be receiving ART, 
and 90% of those receiving ART (i.e., 73% of 
HIV-positive persons) should have viral suppres-
sion; these are the UNAIDS 90-90-90 targets.14 
In 2015, the World Health Organization updated 
its guidelines to recommend immediate ART for 
all HIV-positive persons.15
Although there is compelling evidence sup-
porting the concept of universal testing and 
treatment for HIV prevention, it was not clear 
whether this could be implemented effectively at 
a population level and could affect HIV incidence. 
Four community-randomized trials in sub-Saha-
ran Africa addressed these questions: two (Treat-
ment as Prevention [TasP] and Sustainable East 
Africa Research in Community Health [SEARCH]) 
showed no effect on HIV incidence; a third (Ya 
Tsie) showed a 30% lower incidence of HIV infec-
tion in the intervention group than in the stan-
dard-care group, but the difference was not sig-
nificant.16-18 Here we report the primary results of 
the fourth trial, HPTN 071 (PopART). We also 
describe the uptake of the combination preven-
tion intervention used in the trial and its effect on 
viral suppression.
Me thods
Trial Design
The trial was designed by members of the HPTN 
071 (PopART) Study Team with input from the 
sponsor (the National Institute of Allergy and 
Infectious Diseases), other funders, and govern-
ment and nongovernmental partners in Zambia 
and South Africa, listed in the acknowledgments 
at the end of the article. The data were collected 
by staff of Zambart and the Desmond Tutu Tuber-
culosis Center in collaboration with the London 
School of Hygiene and Tropical Medicine (LSHTM) 
and the HPTN Statistical and Data Management 
Center. The authors vouch for the completeness 
and accuracy of the data and for the fidelity of 
the trial to the protocol, available with the full 
text of this article at NEJM.org. The trial design 
has been described previously19 and is summa-
rized below.
Trial Population
The trial was conducted from 2013 through 
2018, in 21 urban or periurban communities in 
Zambia and Western Cape Province, South Africa 
(total population, approximately 1 million; mean, 
approximately 50,000 per community). Each com-
munity was the catchment population of a gov-
ernment clinic. Communities were grouped in 
seven triplets matched on the basis of geograph-
ic location and estimated HIV prevalence. Com-
munities in each triplet were randomly assigned 
to three trial groups in simultaneous public cere-
monies. Restricted randomization was used to 
ensure balance across the trial groups with re-
spect to population size, baseline ART coverage 
(the percentage of HIV-positive persons who 
were receiving ART), and HIV prevalence.19
Randomization and locations of the trial 
communities are shown in Figure S1 in the 
Supplementary Appendix, available at NEJM.org. 
Group A communities received a combination 
prevention intervention (described below) with 
universal ART. Group B communities received a 
combination prevention intervention with ART 
provided according to local guidelines. Group C 
communities did not receive a combination pre-
vention intervention but received standard care 
A Quick Take 
is available at 
NEJM.org
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at government clinics, including HIV testing and 
ART offered according to local guidelines.
Intervention
The combination prevention intervention (Fig. S2 
in the Supplementary Appendix) was delivered to 
group A and B communities. Specially trained 
community health workers (community HIV-care 
providers) delivered services at annual household 
visits (see the Supplementary Appendix). The 
community health workers worked in pairs, with 
each pair responsible for approximately 500 
households. Data that were collected by the com-
munity health workers were used primarily to 
support service delivery but also to evaluate in-
tervention coverage.
At each visit, the community health workers 
offered HIV counseling and rapid testing, and 
they provided support for linkage to care and 
ART adherence for HIV-positive clients. They re-
ferred uncircumcised HIV-negative men for vol-
untary medical male circumcision and referred 
HIV-positive pregnant women for antenatal care, 
including prevention of mother-to-child HIV 
transmission. The community health workers 
also screened clients for symptoms of tuberculo-
sis and sexually transmitted infections, with re-
ferral for diagnosis and treatment, and promoted 
and provided condoms.
In all 21 communities, HIV care and ART were 
provided at local government clinics. In group A, 
these clinics offered ART irrespective of CD4 cell 
count throughout the trial, with written consent 
for patients initiating ART outside local guide-
lines until universal ART became standard. In 
groups B and C, the clinics provided ART ini-
tially at a CD4 threshold of 350 cells per micro-
liter, which increased to 500 cells per microliter 
in 2014. Universal ART was offered from April 
2016 onward (in Zambia) and October 2016 on-
ward (in South Africa) (Fig. S3 in the Supple-
mentary Appendix).
Outcome Evaluation
The effect of the intervention on population-
level HIV incidence was measured in a popula-
tion cohort (enrolled from December 2013 to 
March 2015) that included one randomly select-
ed adult 18 to 44 years of age from a random 
sample of households in each community (Fig. 
S4 in the Supplementary Appendix). Participants 
were surveyed at baseline and after 12, 24, and 
36 months. Because the original enrollment tar-
get (2500 adults per community) was not reached 
at baseline, additional participants were enrolled at 
12 months and in groups A and C only at 24 
months, excluding households sampled previously.
At each visit, participants were interviewed by 
a field research assistant (separate from the com-
munity health workers) using a structured ques-
tionnaire that included the collection of demo-
graphic, socioeconomic, and behavioral data as 
well as data related to HIV prevention, diagnosis, 
and treatment. After the interview, blood was 
collected by a research nurse, who also offered 
HIV rapid testing to all participants.
The predefined primary outcome was HIV in-
cidence between 12 and 36 months, comparing 
group A with group C and comparing group B 
with group C. This approach provided 1 year to 
fully establish the trial intervention before mea-
surement of trial outcomes. Because the group A 
and group B interventions were equivalent dur-
ing most of the primary analysis period, we also 
report a post hoc analysis of groups A and B 
combined as compared with group C. Other 
outcomes that are reported here include viral 
suppression (<400 copies of HIV RNA per milli-
liter) and the estimated coverage of HIV testing 
and ART on the basis of data from groups A and 
B that were collected by the community health 
workers.
Laboratory Methods
Laboratory-based HIV testing was performed for 
all participants at all visits. Central laboratories 
in South Africa and Zambia performed a single 
fourth-generation HIV test. The HPTN Labora-
tory Center (Baltimore) performed additional test-
ing to determine HIV status (see the Supplemen-
tary Appendix). If seroconversion was confirmed, 
testing was performed to determine whether the 
participant had acute infection at the previous 
visit. HIV viral-load testing was performed at the 
HPTN Laboratory Center for selected samples: 
all HIV-positive participants at 24 months and a 
random subgroup of approximately 75 HIV-pos-
itive participants per community at 0, 12, and 36 
months. HIV viral-load testing was performed with 
the RealTime HIV-1 assay (Abbott Molecular), 
with a level of less than 400 copies of HIV RNA 
per milliliter as the threshold of quantification.
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on July 18, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;3 nejm.org July 18, 2019210
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Ethical Considerations
All participants in the population cohort pro-
vided written informed consent before enroll-
ment. Community members who were visited by 
the community health workers provided verbal 
consent for participation in the intervention and 
data collection. In group A, clinic patients pro-
vided written informed consent when ART was 
initiated outside of prevailing local guidelines 
(from 2013 to 2016). Ethical approval for the 
trial was granted by ethics committees at the 
LSHTM, University of Zambia, and Stellenbosch 
University.
Statistical Analysis
Sample-size calculations were informed by initial 
projections of intervention effect based on math-
ematical modeling,19,20 which suggested that HIV 
incidence might be lower by up to 60% in group 
A and up to 25% in group B than in group C. 
Under the assumption of an HIV incidence in 
group C of 1.0 to 1.5 per 100 person-years, a 
between-community coefficient of variation with-
in matched triplets of 0.15 to 0.20, a total of 
2500 participants per community with 85% HIV-
negative status at baseline, and 25% loss to fol-
low-up over a period of 3 years, the power of the 
trial would exceed 75% or 85% for effects of 
35% or 40%, respectively.
Analysis methods are described in detail in 
the statistical analysis plan (available with the 
protocol), which was completed before data un-
blinding,21 and in the Supplementary Appendix. 
In brief, HIV incidence was measured among 
participants who were HIV-negative at enroll-
ment; HIV infection was assumed to occur at the 
midpoint between the last HIV-negative sample 
and the first HIV-positive sample, or at a visit in 
which acute infection was identified. When the 
time of infection was unclear because of missed 
visits, it was estimated by means of imputation 
(see the Supplementary Appendix, including Table 
S2). For the primary outcome, statistical infer-
ence used a two-stage approach recommended 
for cluster-randomized trials with fewer than 15 
clusters per group.22,23 In groups A and B, data 
that were collected by the community health 
workers were used to estimate the percentage of 
HIV-positive community members who knew 
their HIV status and were receiving ART, accord-
ing to methods and assumptions described in 
the Supplementary Appendix.
R esult s
Enrollment and Follow-up
The enrollment and follow-up of the population 
cohort are shown in Figure 1. A total of 38,474 
adults were enrolled at baseline, with 5014 ad-
ditional enrollments at 12 months and 4813 at 
24 months (total enrolled, 48,301).
At 12 months and again at 24 months, 13% 
of the participants discontinued the trial, most 
because of confirmed permanent relocation out 
of the trial community (Table S3 in the Supple-
mentary Appendix), and their data were cen-
sored from further observation; approximately 
75% of the remaining participants completed 
each visit. The final survey at 36 months reached 
72% of eligible participants, with similar reten-
tion across the trial groups (73%, 73%, and 71% 
in groups A, B, and C, respectively).
Baseline Comparisons
More women (71%) than men (29%) were en-
rolled, with 40% of the participants younger than 
25 years of age (Table 1). Sociodemographic and 
behavioral characteristics were similar across 
the trial groups (Table 1, and Table S1 in the 
Figure 1 (facing page). Enrollment and Follow-up  
of the Population Cohort.
The trial included 21 communities that were matched 
in seven sets of 3 communities each; the 3 communi‑
ties in each triplet were randomly assigned to group A 
(combination prevention intervention with universal 
antiretroviral therapy [ART]), group B (combination 
prevention intervention with ART provided according 
to local guidelines), or group C (standard care). The 
purpose of the population cohort was to enroll and fol‑
low a representative sample of residents to assess the 
effect of the combination prevention intervention on 
the incidence of human immunodeficiency virus (HIV) 
infection and on viral suppression. Participants in the 
population cohort were enrolled from randomly select‑
ed households in the community, with one member 18 
to 44 years of age selected at random for eligibility as‑
sessment. A total of 38,474 participants were enrolled 
at the start of the trial. Additional participants were 
 enrolled at 12 months in communities with fewer than 
2000 participants at the start of the trial; additional par‑
ticipants were enrolled in groups A and C at 24 months 
to preserve power for this comparison. (Values for par‑
ticipant enrollment in each triplet are for the entire trial.) 
The status of participants at each survey year (12, 24, 
and 36 months) is reported. Participants who missed 
yearly follow‑up visits were eligible to complete subse‑
quent annual surveys, whereas participants who dis‑
continued the trial were not.
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on July 18, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;3 nejm.org July 18, 2019 211
Universal Testing and Treatment for HIV
21
 C
om
m
un
iti
es
 in
 Z
am
bi
a 
an
d 
So
ut
h 
A
fr
ic
a
12
 C
om
m
un
iti
es
 in
 Z
am
bi
a 
un
de
rw
en
t r
an
do
m
iz
at
io
n
9 
C
om
m
un
iti
es
 in
 S
ou
th
 A
fr
ic
a 
un
de
rw
en
t r
an
do
m
iz
at
io
n
3 
C
om
m
un
iti
es
 w
ith
 5
73
8
pa
rt
ic
ip
an
ts
 w
er
e
in
cl
ud
ed
 in
 tr
ip
le
t 7
19
65
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 A
20
86
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 B
16
87
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 C
3 
C
om
m
un
iti
es
 w
ith
 7
85
1
pa
rt
ic
ip
an
ts
 w
er
e
in
cl
ud
ed
 in
 tr
ip
le
t 6
27
70
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 A
24
53
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 B
26
28
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 C
3 
C
om
m
un
iti
es
 w
ith
 7
24
5
pa
rt
ic
ip
an
ts
 w
er
e
in
cl
ud
ed
 in
 tr
ip
le
t 5
24
97
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 A
25
33
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 B
22
15
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 C
3 
C
om
m
un
iti
es
 w
ith
 6
90
5
pa
rt
ic
ip
an
ts
 w
er
e
in
cl
ud
ed
 in
 tr
ip
le
t 4
27
84
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 A
20
15
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 B
21
06
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 C
3 
C
om
m
un
iti
es
 w
ith
 7
20
3
pa
rt
ic
ip
an
ts
 w
er
e
in
cl
ud
ed
 in
 tr
ip
le
t 3
24
89
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 A
19
60
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 B
27
54
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 C
3 
C
om
m
un
iti
es
 w
ith
 7
78
5
pa
rt
ic
ip
an
ts
 w
er
e
in
cl
ud
ed
 in
 tr
ip
le
t 2
26
60
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 A
24
37
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 B
26
88
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 C
12
,6
71
 P
ar
tic
ip
an
ts
 fr
om
 7
 c
om
m
un
iti
es
w
er
e 
in
 g
ro
up
 A
 a
t s
ta
rt
 o
f t
he
 tr
ia
l
13
,4
04
 P
ar
tic
ip
an
ts
 fr
om
 7
 c
om
m
un
iti
es
w
er
e 
in
 g
ro
up
 B
 a
t s
ta
rt
 o
f t
he
 tr
ia
l
12
,3
99
 P
ar
tic
ip
an
ts
 fr
om
 7
 c
om
m
un
iti
es
w
er
e 
in
 g
ro
up
 C
 a
t s
ta
rt
 o
f t
he
 tr
ia
l
12
,3
54
 W
er
e 
av
ai
la
bl
e 
fo
r 
24
-m
o 
fo
llo
w
-u
p
13
,7
32
 W
er
e 
av
ai
la
bl
e 
fo
r 
24
-m
o 
fo
llo
w
-u
p
12
,2
11
 W
er
e 
av
ai
la
bl
e 
fo
r 
24
-m
o 
fo
llo
w
-u
p
12
-M
o 
fo
llo
w
-u
p
12
-M
o 
fo
llo
w
-u
p
12
-M
o 
fo
llo
w
-u
p
3 
C
om
m
un
iti
es
 w
ith
 5
57
4
pa
rt
ic
ip
an
ts
 w
er
e
in
cl
ud
ed
 in
 tr
ip
le
t 1
16
33
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 A
18
87
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 B
20
54
 W
er
e 
en
ro
lle
d
in
 g
ro
up
 C
20
31
 (
16
%
) 
D
is
co
nt
in
ue
d 
tr
ia
l
24
07
 (
19
%
) 
M
is
se
d 
fo
llo
w
-u
p
82
33
 (
65
%
) 
C
om
pl
et
ed
 fo
llo
w
-u
p 
as
se
ss
m
en
t
17
14
 W
er
e 
ad
de
d 
to
 p
op
ul
at
io
n 
co
ho
rt
16
39
 (
12
%
) 
D
is
co
nt
in
ue
d 
tr
ia
l
31
93
 (
24
%
) 
M
is
se
d 
fo
llo
w
-u
p
85
72
 (
64
%
) 
C
om
pl
et
ed
 fo
llo
w
-u
p 
as
se
ss
m
en
t
19
67
 W
er
e 
ad
de
d 
to
 p
op
ul
at
io
n 
co
ho
rt
15
21
 (
12
%
) 
D
is
co
nt
in
ue
d 
tr
ia
l
23
94
 (
19
%
) 
M
is
se
d 
fo
llo
w
-u
p
84
84
 (
68
%
) 
C
om
pl
et
ed
 fo
llo
w
-u
p 
as
se
ss
m
en
t
13
33
 W
er
e 
ad
de
d 
to
 p
op
ul
at
io
n 
co
ho
rt
13
,1
64
 W
er
e 
av
ai
la
bl
e 
fo
r 
36
-m
o 
fo
llo
w
-u
p
12
,1
24
 W
er
e 
av
ai
la
bl
e 
fo
r 
36
-m
o 
fo
llo
w
-u
p
12
,7
79
 W
er
e 
av
ai
la
bl
e 
fo
r 
36
-m
o 
fo
llo
w
-u
p
24
-M
o 
fo
llo
w
-u
p
24
-M
o 
fo
llo
w
-u
p
24
-M
o 
fo
llo
w
-u
p
16
03
 (
13
%
) 
D
is
co
nt
in
ue
d 
tr
ia
l
26
32
 (
21
%
) 
M
is
se
d 
fo
llo
w
-u
p
81
19
 (
66
%
) 
C
om
pl
et
ed
 fo
llo
w
-u
p 
as
se
ss
m
en
t
24
13
 W
er
e 
ad
de
d 
to
 p
op
ul
at
io
n 
co
ho
rt
16
08
 (
12
%
) 
D
is
co
nt
in
ue
d 
tr
ia
l
28
70
 (
21
%
) 
M
is
se
d 
fo
llo
w
-u
p
92
54
 (
67
%
) 
C
om
pl
et
ed
 fo
llo
w
-u
p 
as
se
ss
m
en
t
0 
W
er
e 
ad
de
d 
to
 p
op
ul
at
io
n 
co
ho
rt
18
32
 (
15
%
) 
D
is
co
nt
in
ue
d 
tr
ia
l
25
57
 (
21
%
) 
M
is
se
d 
fo
llo
w
-u
p
78
22
 (
64
%
) 
C
om
pl
et
ed
 fo
llo
w
-u
p 
as
se
ss
m
en
t
24
00
 W
er
e 
ad
de
d 
to
 p
op
ul
at
io
n 
co
ho
rt
36
-M
o 
fo
llo
w
-u
p
36
-M
o 
fo
llo
w
-u
p
36
-M
o 
fo
llo
w
-u
p
35
73
 (
27
%
) 
D
is
co
nt
in
ue
d 
tr
ia
l
95
91
 (
73
%
) 
C
om
pl
et
ed
 fo
llo
w
-u
p 
as
se
ss
m
en
t
33
30
 (
27
%
) 
D
is
co
nt
in
ue
d 
tr
ia
l
87
94
 (
73
%
) 
C
om
pl
et
ed
 fo
llo
w
-u
p 
as
se
ss
m
en
t
36
63
 (
29
%
) 
D
is
co
nt
in
ue
d 
tr
ia
l
91
16
 (
71
%
) 
C
om
pl
et
ed
 fo
llo
w
-u
p 
as
se
ss
m
en
t
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on July 18, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;3 nejm.org July 18, 2019212
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Characteristic
Group A 
(N = 12,671)
Group B 
(N = 13,404)
Group C 
(N = 12,399)
number/total number (percent)
Sex
Male 3595/12,637 (28) 3906/13,364 (29) 3701/12,340 (30)
Female 9042/12,637 (72) 9458/13,364 (71) 8639/12,340 (70)
Age
18–24 yr 5065/12,636 (40) 5179/13,364 (39) 4981/12,336 (40)
25–34 yr 4928/12,636 (39) 5170/13,364 (39) 4688/12,336 (38)
35–44 yr 2643/12,636 (21) 3015/13,364 (23) 2667/12,336 (22)
Marital status
Married or living as married 5363/12,560 (43) 5210/13,233 (39) 4693/12,199 (38)
Never married 6292/12,560 (50) 6923/13,233 (52) 6644/12,199 (54)
Divorced, separated, or widowed 905/12,560 (7) 1100/13,233 (8) 862/12,199 (7)
Male circumcision status†
Not circumcised 1725/3405 (51) 1974/3758 (53) 1904/3445 (55)
Medical circumcision 567/3405 (17) 613/3758 (16) 646/3445 (19)
Traditional circumcision 1113/3405 (33) 1171/3758 (31) 895/3445 (26)
Current use of ART by HIV‑positive participants†
Yes 788/2375 (33) 1048/2582 (41) 878/2526 (35)
No 1587/2375 (67) 1534/2582 (59) 1648/2526 (65)
HIV status‡
Negative 9594/12,177 (79) 10,235/12,969 (79) 9301/11,988 (78)
Positive 2583/12,177 (21) 2734/12,969 (21) 2687/11,988 (22)
HSV‑2 status§
Negative 6506/12,237 (53) 7005/13,019 (54) 6585/12,016 (55)
Positive 5667/12,237 (46) 5959/13,019 (46) 5357/12,016 (45)
Indeterminate 64/12,237 (1) 55/13,019 (<1) 74/12,016 (1)
HIV viral suppression¶
Yes 295/523 (56) 300/525 (57) 267/494 (54)
No 228/523 (44) 225/525 (43) 227/494 (46)
*  The table is restricted to participants who were enrolled in the population cohort at baseline (month 0). Data are pooled 
across all seven communities in each trial group. Group A communities received a combination prevention intervention 
with universal antiretroviral therapy (ART). Group B communities received a combination prevention intervention with 
ART provided according to local guidelines. Group C communities received standard care. Percentages may not total 100 
because of rounding. HIV denotes human immunodeficiency virus, and HSV‑2 herpes simplex virus type 2.
†  Status regarding male circumcision was reported by the participants, as was use or nonuse of ART by HIV‑positive par‑
ticipants.
‡  HIV status was not determined when a participant did not consent to specimen collection, when no sample was avail‑
able, or when laboratory testing did not result in a determination of infection status.
§  HSV‑2 status was not determined when a participant did not consent to specimen collection or when no sample was 
available.
¶  Viral suppression was assessed in a random sample of approximately 75 HIV‑positive participants per community at 
baseline.
Table 1. Characteristics of the Population Cohort at Baseline.*
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Universal Testing and Treatment for HIV
Supplementary Appendix). Approximately 17% of 
the men reported having undergone medical 
circumcision.
The baseline HIV prevalence was 22% (women, 
26%; men, 12%), and the baseline herpes sim-
plex virus type 2 (HSV-2) prevalence was 46% 
(women, 54%; men, 24%). The prevalence of 
both infections was similar across the trial 
groups (HIV, 21% in group A, 21% in group B, 
and 22% in group C; HSV-2, 46% in group A, 
46% in group B, and 45% in group C). Reported 
ART coverage was highest in group B (33% in 
group A, 41% in group B, and 35% in group C), 
but the percentage of HIV-positive participants 
who had viral suppression at baseline was simi-
lar across the trial groups (56% in group A, 57% 
in group B, and 54% in group C).
Effect of the Intervention on HIV Incidence
Estimated effects of the intervention on HIV 
incidence are shown in Table 2 and Figure 2. 
Between 12 and 36 months (primary outcome), 
553 incident HIV infections were observed dur-
ing 39,702 person-years (overall incidence, 1.4 per 
100 person-years; women, 1.7 per 100 person-
years; men, 0.8 per 100 person-years). The inci-
dence in group C (geometric mean across com-
munities) was 1.6 per 100 person-years (Table 2). 
The incidence in group A was 1.5 per 100 person-
years; the adjusted rate ratio as compared with 
group C was 0.93 (95% confidence interval [CI], 
0.74 to 1.18; P = 0.51). The incidence in group B 
was 1.1 per 100 person-years; the adjusted rate 
ratio as compared with group C was 0.70 (95% 
CI, 0.55 to 0.88; P = 0.006). HIV incidence was 
lower in group B than in group C in all seven 
matched triplets, whereas the incidence was 
lower in group A than in group C in four triplets 
(Fig. 2). A permutation test based on the restrict-
ed randomization scheme showed even stronger 
evidence of an effect in group B as compared 
with group C (P = 0.001), but not in group A as 
compared with group C (P = 0.48). The findings 
were similar when the analysis was restricted to 
participants enrolled at baseline (Table S7 in the 
Supplementary Appendix).
In group B as compared with group C, sub-
group analyses according to sex (Table 2) and 
age and sex (Table S4 in the Supplementary Ap-
pendix) showed a greater effect on HIV incidence 
in men (adjusted rate ratio, 0.52; 95% CI, 0.24 to 
1.12) than in women (adjusted rate ratio, 0.73; 
95% CI, 0.55 to 0.97), although this difference in 
effect could have occurred by chance (P = 0.40 
for interaction). There was also evidence of a 
greater effect in older participants (adjusted rate 
ratio in participants ≥25 years of age, 0.58; 95% 
CI, 0.43 to 0.76) than in younger participants 
(adjusted rate ratio in participants 18 to 24 years 
of age, 0.92; 95% CI, 0.70 to 1.20; P = 0.04 for 
interaction). HIV incidence and estimated effects 
for individual years of follow-up and for the en-
tire trial period (0 to 36 months) are shown in 
Tables S4 and S5 in the Supplementary Appen-
dix. HIV incidence decreased in group C by 12% 
(95% CI, 0 to 23) per year (Fig. S5 in the Supple-
mentary Appendix). HIV incidence was approxi-
mately 20% lower in groups A and B combined 
than in group C (adjusted rate ratio, 0.81; 95% 
CI, 0.66 to 0.99).
Effect of the Intervention on Viral 
Suppression
The percentage of HIV-positive participants at 24 
months who met our case definition of viral 
suppression was 71.9% in group A, 67.5% in 
group B, and 60.2% in group C (Table 2). The 
adjusted prevalence ratio for viral suppression in 
group A as compared with group C was 1.16 
(95% CI, 0.99 to 1.36; P = 0.07), and the ratio in 
group B as compared with group C was 1.08 
(95% CI, 0.92 to 1.27; P = 0.30). In groups A and B, 
the prevalence of viral suppression at 24 months 
was higher among women than among men and 
higher among participants 25 years of age or 
older than among those 18 to 24 years of age 
(Table 2, and Table S8 in the Supplementary Ap-
pendix). The prevalence of viral suppression in 
groups A and B increased from approximately 
55% at baseline to approximately 75% at 36 
months and was 86 to 91% among participants 
in groups A and B who reported ART use (Tables 
S9 and S10 in the Supplementary Appendix).
Coverage of the Intervention
On the basis of data collected by the community 
health workers, the estimated percentage of all 
HIV-positive adults in the community who were 
receiving ART at the end of the trial was 81% in 
group A and 80% in group B (Table S11 in the 
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on July 18, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;3 nejm.org July 18, 2019214
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Ta
bl
e 
2.
 E
ff
ec
t o
f t
he
 C
om
bi
na
tio
n 
Pr
ev
en
tio
n 
In
te
rv
en
tio
n 
on
 H
IV
 In
ci
de
nc
e 
an
d 
H
IV
 V
ir
al
 S
up
pr
es
si
on
.*
V
ar
ia
bl
e
G
ro
up
 A
G
ro
up
 B
G
ro
up
 C
G
ro
up
 A
 v
s.
 G
ro
up
 C
G
ro
up
 B
 v
s.
 G
ro
up
 C
A
dj
us
te
d 
R
at
e 
R
at
io
 
(9
5%
 C
I)
†
P 
V
al
ue
A
dj
us
te
d 
R
at
e 
R
at
io
 
(9
5%
 C
I)
†
P 
V
al
ue
no
./
to
ta
l p
er
so
n-
yr
 (
ra
te
 p
er
 1
00
 p
er
so
n-
yr
)
Pa
rt
ic
ip
an
ts
 w
ith
 n
ew
 H
IV
 in
fe
ct
io
n,
 1
2–
36
 m
o‡
Tr
ip
le
t 1
28
/1
68
7 
(1
.6
4)
19
/1
97
9 
(0
.9
4)
24
/2
05
4 
(1
.1
7)
Tr
ip
le
t 2
33
/2
08
6 
(1
.5
7)
29
/2
40
8 
(1
.2
0)
33
/2
26
2 
(1
.4
8)
Tr
ip
le
t 3
23
/1
69
5 
(1
.3
6)
22
/1
68
7 
(1
.3
0)
29
/1
81
1 
(1
.6
3)
Tr
ip
le
t 4
41
/2
01
3 
(2
.0
4)
19
/1
69
8 
(1
.1
3)
37
/1
56
1 
(2
.3
9)
Tr
ip
le
t 5
36
/1
50
7 
(2
.3
5)
33
/1
81
1 
(1
.8
0)
28
/1
30
4 
(2
.1
5)
Tr
ip
le
t 6
26
/1
80
8 
(1
.4
3)
26
/2
07
8 
(1
.2
4)
32
/1
37
5 
(2
.3
1)
Tr
ip
le
t 7
13
/2
19
5 
(0
.5
7)
10
/2
48
8 
(0
.4
0)
14
/2
19
5 
(0
.5
9)
O
ve
ra
ll§
19
8/
12
,9
90
 (
1.
45
)
15
7/
14
,1
49
 (
1.
06
)
19
8/
12
,5
63
 (
1.
55
)
 0
.9
3 
(0
.7
4–
1.
18
)¶
0.
51
¶
 0
.7
0 
(0
.5
5–
0.
88
)¶
0.
00
6¶
M
en
36
/3
76
6 
(0
.7
7)
23
/4
30
1 
(0
.4
5)
39
/4
11
5 
(0
.9
2)
0.
88
 (
0.
41
–1
.8
8)
‖
0.
52
 (
0.
24
–1
.1
2)
‖
W
om
en
16
2/
92
25
 (
1.
71
)
13
4/
98
48
 (
1.
26
)
15
9/
84
48
 (
1.
79
)
0.
96
 (
0.
72
–1
.2
8)
‖
0.
73
 (
0.
55
–0
.9
7)
‖
no
./
to
ta
l H
IV
-p
os
iti
ve
 p
ar
tic
ip
an
ts
 (
%
)
Pa
rt
ic
ip
an
ts
 w
ith
 v
ir
al
 s
up
pr
es
si
on
 a
t 2
4 
m
o*
*
Tr
ip
le
t 1
14
0/
17
5 
(8
0.
0)
18
3/
24
4 
(7
5.
0)
21
2/
29
0 
(7
3.
1)
Tr
ip
le
t 2
20
4/
31
1 
(6
5.
6)
27
6/
37
1 
(7
4.
4)
17
9/
27
1 
(6
6.
1)
Tr
ip
le
t 3
22
5/
29
5 
(7
6.
3)
17
7/
25
5 
(6
9.
4)
17
4/
28
4 
(6
1.
3)
Tr
ip
le
t 4
35
6/
51
8 
(6
8.
7)
21
9/
32
4 
(6
7.
6)
35
4/
47
6 
(7
4.
4)
Tr
ip
le
t 5
27
0/
38
9 
(6
9.
4)
27
5/
38
1 
(7
2.
2)
21
1/
31
5 
(6
7.
0)
Tr
ip
le
t 6
25
0/
35
5 
(7
0.
4)
12
6/
20
2 
(6
2.
4)
33
8/
50
6 
(6
6.
8)
Tr
ip
le
t 7
86
/1
16
 (
74
.1
)
62
/1
14
 (
54
.4
)
12
/4
1 
(2
9.
3)
O
ve
ra
ll§
15
31
/2
15
9 
(7
1.
9)
13
18
/1
89
1 
(6
7.
5)
14
80
/2
18
3 
(6
0.
2)
  
1.
16
 (
0.
99
–1
.3
6)
†
†
0.
07
†
†
  
1.
08
 (
0.
92
–1
.2
7)
†
†
0.
30
†
†
M
en
‡
‡
18
3/
29
4 
(6
3.
0)
15
3/
24
4 
(6
0.
8)
17
9/
33
0 
(4
0.
0)
 1
.4
6 
(0
.8
6–
2.
48
)§
§
 1
.4
1 
(0
.8
3–
2.
41
)§
§
W
om
en
‡
‡
13
48
/1
86
5 
(7
3.
3)
11
65
/1
64
7 
(6
8.
4)
13
01
/1
85
3 
(6
5.
8)
 1
.1
0 
(1
.0
0–
1.
22
)§
§
 1
.0
3 
(0
.9
3–
1.
13
)§
§
* 
 C
I 
de
no
te
s 
co
nf
id
en
ce
 in
te
rv
al
.
†
 
 Th
e 
ad
ju
st
ed
 p
re
va
le
nc
e 
ra
tio
 is
 s
ho
w
n 
fo
r 
vi
ra
l s
up
pr
es
si
on
. F
or
 H
IV
 in
fe
ct
io
n,
 t
he
 r
at
e 
ra
tio
 w
as
 a
dj
us
te
d 
fo
r 
ag
e,
 s
ex
, a
nd
 b
as
el
in
e 
H
IV
 p
re
va
le
nc
e.
 F
or
 v
ir
al
 s
up
pr
es
si
on
, t
he
 p
re
va
‑
le
nc
e 
ra
tio
 w
as
 a
dj
us
te
d 
fo
r 
ag
e 
an
d 
se
x.
‡
 
 Im
pu
ta
tio
n 
w
as
 u
se
d 
to
 e
st
im
at
e 
th
e 
tim
in
g 
of
 H
IV
 in
fe
ct
io
n 
in
 p
ar
tic
ip
an
ts
 w
ith
 s
er
oc
on
ve
rs
io
n 
w
ho
 m
is
se
d 
th
e 
fo
llo
w
‑u
p 
as
se
ss
m
en
t 
at
 1
2 
m
on
th
s 
or
 2
4 
m
on
th
s 
(s
ee
 t
he
 
Su
pp
le
m
en
ta
ry
 A
pp
en
di
x)
. T
he
 e
st
im
at
ed
 o
ve
ra
ll 
nu
m
be
r 
of
 in
fe
ct
io
ns
 in
 e
ac
h 
gr
ou
p 
m
ay
 n
ot
 m
at
ch
 t
he
 t
ot
al
 o
f t
he
 e
st
im
at
ed
 n
um
be
rs
 in
 t
he
 s
ev
en
 t
ri
pl
et
s 
be
ca
us
e 
of
 r
ou
nd
in
g.
§ 
 Th
e 
ov
er
al
l r
at
e 
of
 in
ci
de
nt
 H
IV
 in
fe
ct
io
n 
is
 t
he
 g
eo
m
et
ri
c 
m
ea
n 
of
 t
he
 r
at
es
 in
 in
di
vi
du
al
 c
om
m
un
iti
es
. T
he
 o
ve
ra
ll 
pe
rc
en
ta
ge
 o
f p
ar
tic
ip
an
ts
 w
ith
 v
ir
al
 s
up
pr
es
si
on
 is
 t
he
 g
eo
m
et
ri
c 
m
ea
n 
of
 t
he
 p
er
ce
nt
ag
es
 in
 in
di
vi
du
al
 c
om
m
un
iti
es
.
¶
 
 Th
e 
un
ad
ju
st
ed
 ra
te
 ra
tio
 fo
r g
ro
up
 A
 a
s 
co
m
pa
re
d 
w
ith
 g
ro
up
 C
 w
as
 0
.9
4 
(9
5%
 C
I, 
0.
77
 to
 1
.1
5;
 P
 =
 0.
50
5)
 a
nd
 fo
r g
ro
up
 B
 a
s 
co
m
pa
re
d 
w
ith
 g
ro
up
 C
 w
as
 0
.6
8 
(9
5%
 C
I, 
0.
56
 to
 0
.8
4;
 P
 =
 0.
00
2)
.
‖ 
 Fo
r 
gr
ou
p 
A
 a
s 
co
m
pa
re
d 
w
ith
 g
ro
up
 C
, t
he
 P
 v
al
ue
 fo
r 
in
te
ra
ct
io
n 
ac
co
rd
in
g 
to
 s
ex
 w
as
 0
.7
9.
 F
or
 g
ro
up
 B
 a
s 
co
m
pa
re
d 
w
ith
 g
ro
up
 C
, t
he
 P
 v
al
ue
 fo
r 
in
te
ra
ct
io
n 
ac
co
rd
in
g 
to
 s
ex
 w
as
 0
.4
0.
**
  V
ir
al
 s
up
pr
es
si
on
 w
as
 d
ef
in
ed
 a
s 
an
 H
IV
 v
ir
al
 lo
ad
 o
f l
es
s 
th
an
 4
00
 c
op
ie
s 
pe
r 
m
ill
ili
te
r.
†
†
  T
he
 u
na
dj
us
te
d 
pr
ev
al
en
ce
 r
at
io
 fo
r 
gr
ou
p 
A
 a
s 
co
m
pa
re
d 
w
ith
 g
ro
up
 C
 w
as
 1
.1
9 
(9
5%
 C
I, 
0.
97
 t
o 
1.
47
; P
 =
 0
.0
9)
 a
nd
 fo
r 
gr
ou
p 
B
 a
s 
co
m
pa
re
d 
w
ith
 g
ro
up
 C
 w
as
 1
.1
2 
(9
5%
 C
I, 
0.
91
 t
o 
1.
38
; P
 =
 0
.2
6)
.
‡
‡
  T
he
 s
ex
‑s
pe
ci
fic
 p
er
ce
nt
ag
es
 a
re
 g
eo
m
et
ri
c 
m
ea
ns
 o
f t
he
 p
er
ce
nt
ag
es
 fo
r 
ea
ch
 s
ex
 a
cr
os
s 
th
e 
tr
ia
l c
om
m
un
iti
es
.
§§
 
 Fo
r 
gr
ou
p 
A
 a
s 
co
m
pa
re
d 
w
ith
 g
ro
up
 C
, t
he
 P
 v
al
ue
 fo
r 
in
te
ra
ct
io
n 
ac
co
rd
in
g 
to
 s
ex
 w
as
 0
.2
2.
 F
or
 g
ro
up
 B
 a
s 
co
m
pa
re
d 
w
ith
 g
ro
up
 C
, t
he
 P
 v
al
ue
 fo
r 
in
te
ra
ct
io
n 
ac
co
rd
in
g 
to
 s
ex
 w
as
 0
.1
6.
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on July 18, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;3 nejm.org July 18, 2019 215
Universal Testing and Treatment for HIV
Supplementary Appendix). Figure 3 shows esti-
mated ART coverage according to age and sex, 
with the results indicating similar coverage in 
groups A and B, lower coverage among men 
than among women, and lower coverage among 
younger participants than among older partici-
pants. ART coverage was also similar in groups 
A and B in most triplets (Fig. S6 in the Supple-
mentary Appendix).
Discussion
This trial provides evidence that a combination 
prevention intervention including universal test-
ing and treatment can reduce HIV incidence at 
a population level. HIV incidence was lower by 
30% in group B than in the standard-care con-
trol group; surprisingly, there was no evidence of 
such an effect in group A.
A universal testing and treatment strategy is 
hypothesized to reduce HIV transmission by in-
creasing the percentage of HIV-positive commu-
nity members who know their HIV status, the 
percentage of those persons who are receiving 
ART, and the percentage of those receiving ART 
who have viral suppression. Data from this trial 
indicate that the UNAIDS 90-90-90 targets (with 
testing and treatment leading to 73% viral sup-
pression) were achieved by the end of the 3-year 
intervention in both group A and B communities 
(approximately 75% viral suppression). Higher 
levels of viral suppression were observed among 
HIV-positive population-cohort participants in 
group A and B communities at 24 months than 
at baseline (approximately 70% vs. approximate-
ly 55%).
There are several possible explanations for 
the lack of an effect on HIV incidence when the 
combination prevention intervention was added 
to universal ART (group A). First, written in-
formed consent, required for initiation of ART 
outside local guidelines from the start of the 
trial until 2016, may have inadvertently discour-
aged ART initiation, although this is not sup-
ported by data showing similar ART coverage 
and viral suppression in groups A and B. Second, 
wide-scale ART delivery in group A may have led 
to sexual disinhibition or de-emphasis of primary 
prevention, offsetting the observed increase in 
viral suppression. Data on participant-reported 
risk behaviors do not support this hypothesis; 
further analyses are planned once data on HSV-2 
seroconversion (a proxy for sexual risk behavior) 
become available. Third, although the three trial 
groups appeared well matched at baseline, there 
may have been unrecognized differences across 
communities in sociodemographic or other fac-
tors, such as mobility and migration resulting in 
exposure to HIV-positive partners from other 
Figure 2. Estimates of HIV Incidence and Log Ratio Residuals for the Seven 
Triplets (Three Communities Each).
The plots show estimates of HIV incidence (plotted per 100 person‑years) 
(Panel A) and log ratio residuals (ratio of observed to expected HIV infec‑
tions, with adjustment for age, sex, and baseline HIV prevalence) (Panel B) 
for group A as compared with group C and for group B as compared with 
group C. Data are shown for the trial period included in the primary out‑
come analysis (between months 12 and 36). Colored lines represent each 
of the seven triplets (numbered 1 to 7). For HIV incidence, the size of the 
colored dot at the end of each line represents the number of events con‑
tributing to the incidence estimate for each community.
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communities. Although these urban communi-
ties had high mobility, analysis of available data 
does not suggest any appreciable differences in 
migration across the trial groups. Further analy-
ses of qualitative and quantitative data from the 
trial communities, and data from an ongoing 
phylogenetic study, may shed light on the unex-
pected result in group A.
In the absence of alternative explanations and 
given that the interventions in groups A and B 
were identical for most of the primary analysis 
period, it is possible that the difference in ob-
served effects was due to chance. This possibil-
ity underlay our decision to carry out a post hoc 
analysis combining groups A and B, which 
showed a 20% lower HIV incidence than in 
group C.
Strengths of the trial included the large 
sample size, enrollment of a randomly sampled 
cohort to measure HIV incidence and viral sup-
pression at the community level, delivery of ART 
through routine services at government clinics, 
extensive process data used to refine delivery of 
the intervention, and strong community engage-
ment. Although our trial communities were not 
chosen to be representative of Zambia or South 
Africa as a whole, conduct of the trial in large 
urban communities with high mobility should 
increase the generalizability of the findings to 
other urban areas of southern Africa with wide-
spread HIV epidemics.
One limitation is that data on uptake of inter-
ventions among HIV-positive participants in the 
population cohort may be subject to a Hawthorne 
effect, because participants had regular contact 
with research staff offering HIV testing and 
providing referral to care. This Hawthorne effect 
would probably be greatest in group C, in which 
participants did not have access to the services 
provided by the community health workers for 
testing and referral. Thus, for uptake estimates, 
we relied mainly on intervention data, which were 
available only for group A and B communities. 
In addition, men were underrepresented in the 
population cohort, and a substantial number of 
participants moved out of the community during 
follow-up, so their data were censored from fur-
ther observation. Thus, we cannot rule out selec-
tion bias, although there was no evidence that 
these factors differed between trial groups.
The results of the HPTN 071 (PopART) trial 
are consistent with programmatic and survey 
data24-27 and should be considered alongside 
those of the other three trials that measured the 
effect of universal testing and treatment on HIV 
incidence in Africa, all of which were smaller 
and undertaken in largely rural communities. 
The TasP trial16 showed no effect on HIV inci-
dence, which may have reflected the similar HIV 
testing services provided in the intervention and 
control groups, with low levels of ART coverage 
in both groups. The SEARCH trial17 also showed 
no effect on HIV incidence, which may have re-
flected intensive baseline community-based HIV 
testing in both the intervention and control 
groups. The Ya Tsie trial18 showed a 30% lower 
incidence in the intervention group than in the 
control group, but the difference was not sig-
nificant.
Our finding of a 20 to 30% reduction in HIV 
incidence at a population level was measured 
against a background of decreasing incidence in 
Figure 3. Estimated ART Coverage at the End of the Trial, According to Age, 
Sex, and Trial Group.
The plot shows estimated ART coverage among the total population 15 
years of age or older in group A and B communities at the end of the trial, 
according to sex, age group, and trial group. (Estimates are based on data 
collected by community health workers.) The Joint United Nations Program 
on HIV/AIDS 90‑90‑90 target for ART coverage (81%) is shown in red. The 
estimated number of HIV‑positive men who were resident in the community 
at the time that community health workers first visited their household 
during the third (and last) annual round of the intervention, and remained 
resident in the trial community at the end of the trial, was 8388 in group A 
and 8948 in group B, and the estimated number of women in this category 
was 15,936 in group A and 17,586 in group B. The estimated number of 
HIV‑positive men receiving ART was 6286 in group A and 6378 in group B, 
and the estimated number of HIV‑positive women receiving ART was 
13,600 in group A and 14,481 in group B.
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communities providing standard care, possibly 
attributable to gradually increasing coverage of 
ART in the general population. This indicates 
that combination prevention including universal 
testing and treatment can make a substantial 
contribution to HIV epidemic control. It is nota-
ble that the effects seen in our trial, the Ya Tsie 
trial, and others28 were achieved by delivering 
intensive household-based HIV-testing services; 
this may have played a more important role than 
changes in ART guidelines. The universal “test” 
component of a “test and treat” strategy is vital, 
as is continued attention to primary HIV preven-
tion interventions.29,30 Results from planned cost-
effectiveness and modeling studies will provide 
information on the cost-effectiveness (value for 
money) and longer-term effect of such strategies, 
which will help to inform policy and practice. Data 
on ART coverage from the HPTN 071 (PopART) 
trial, like data from other studies, draw special 
attention to the challenges in achieving ART cov-
erage targets in young people, men, and com-
munities with high mobility.31-33 If HIV transmis-
sion is concentrated in these subgroups, the effect 
of universal testing and treatment on HIV trans-
mission may be compromised. Special efforts 
will be needed to address these coverage gaps to 
realize the full potential of universal testing and 
treatment for HIV epidemic control.
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